Voyager Therapeutics

VYGR Rare disease Lead: Phase 1 8 Biotech Distilled articles ↓

Most recent annual filing: 2026-03-09

Catalyst timeline

NBIB-'223 Friedreich's ataxia trial start2026NBIB-'223 Friedreich's ataxia trial start, 2026, routine
BIIB080 Biogen Ph2 readoutMid-2026BIIB080 Biogen Ph2 readout, Mid-2026, major
VY7523 interim4Q 2026VY7523 interim, 4Q 2026, major
VY1706 trial start4Q 2026VY1706 trial start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

VY1706

Gene Therapy Target: tau mRNA, tau, MAPT

Alzheimer's Disease Preclinical intravenous NCT07764146

VY7523

Protein Target: tau

Alzheimer's Disease Phase 1 intravenous NCT06874621

frataxin gene therapy

NBIB-'223

Gene Therapy Target: FXN

Friedreich's Ataxia Preclinical intravenous Neurocrine Biosciences

glucosylceramidase beta 1 gene therapy

Gene Therapy Target: GBA1

Gaucher Disease Preclinical intravenous Neurocrine Biosciences
Parkinson's Disease Preclinical intravenous Neurocrine Biosciences

TDP-43 targeting small molecule

Small Molecule Target: TDP-43

Amyotrophic Lateral Sclerosis Preclinical Transition Bio
Frontotemporal Dementia Preclinical Transition Bio

selective small molecules

Small Molecule Target: TDP-43

Amyotrophic Lateral Sclerosis Preclinical Transition Bio
Frontotemporal Dementia Preclinical Transition Bio

Technology platforms

TRACER

Tropism Redirection of AAV by Cell-type-specific Expression of RNA — RNA-based AAV capsid discovery platform enabling rapid discovery of capsids with robust BBB penetration and enhanced CNS tropism in multiple species including NHPs; used to generate novel capsids for intravenously delivered AAV gene therapies targeting neurological diseases including Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, SMA, and Huntington's disease.

Targets: ALPL, ApoE4, ApoE2

Voyager NeuroShuttle

Non-viral delivery platform leveraging novel receptor-binding molecules (initially ALPL receptor) to transport multiple modalities of neurotherapeutics across the blood-brain barrier; early discovery stage targeting undisclosed neurological disease; demonstrated sustained brain expression over three weeks in murine proof-of-concept studies.

Targets: ALPL

Biotech Distilled coverage (8)

2026-08-07 UPDATE: Voyager Therapeutics (VYGR) - The Catalysts Slide Into Q4 🔒 Paid
2026-06-10 UPDATE: Voyager Therapeutics (VYGR) - The War-Chest Vote Passes
2026-06-02 UPDATE: Voyager Therapeutics (VYGR) - The IND Lands
2026-05-16 UPDATE: Voyager Therapeutics (VYGR) - EcoR1 Walks 🔒 Paid
2026-05-14 UPDATE: Voyager Therapeutics (VYGR) - The AAV Liver Ghost Got Quieter 🔒 Paid
2026-05-08 UPDATE: Voyager Therapeutics (VYGR) - The Q1 Print Answers Two Open Questions 🔒 Paid
2026-04-27 UPDATE: Voyager Therapeutics (VYGR) - The Second C-Suite Exit and the 240M-Share Tell 🔒 Paid
2026-03-17 Voyager Therapeutics (VYGR) - Scientific Deep Dive for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.